{"gene":"CDKN1C","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":2012,"finding":"Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome and result in loss of PCNA binding. Targeted expression of IMAGe-associated CDKN1C mutations in Drosophila caused severe eye growth defects compared to wild-type CDKN1C, indicating a gain-of-function mechanism. IMAGe mutations are distinct from BWS-causing mutations in CDKN1C.","method":"Identity-by-descent analysis, targeted exon capture/sequencing, dideoxy sequencing, Drosophila transgenic overexpression assay","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods including functional in vivo assay in Drosophila, sequencing validation, and PCNA-binding loss demonstrated; replicated across multiple unrelated patients","pmids":["22634751"],"is_preprint":false},{"year":2013,"finding":"IMAGe-associated mutations in the PCNA-binding domain of CDKN1C dramatically increase protein stability via impaired proteasome-mediated degradation, explaining the gain-of-function reduced-growth phenotype. Wild-type CDKN1C is degraded via the proteasome (blocked by MG132), whereas IMAGe mutants (e.g. p.Ile272Ser, p.Asp274Asn, p.Phe276Val) are resistant to degradation. PCNA binding to CDKN1C is disrupted by these mutations.","method":"Western blotting with cycloheximide chase, proteasome inhibitor (MG132) treatment, co-immunoprecipitation for PCNA binding","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (cycloheximide chase, MG132 rescue, PCNA binding assay) in single rigorous study; finding replicated by independent lab (PMID 25861374)","pmids":["24098681","25861374"],"is_preprint":false},{"year":2015,"finding":"IMAGe-associated mutations in the PCNA-binding site of CDKN1C significantly increase CDKN1C protein stability and prevent cell cycle progression into S phase. Overexpression of either wild-type or BWS-mutant CDKN1C inhibited cell proliferation, but IMAGe-mutant CDKN1C decreased cell growth significantly more than wild-type or BWS protein.","method":"Flow cytometry cell cycle analysis, Western blotting, cell proliferation assays","journal":"Cell division","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean functional assays with multiple cell cycle readouts, single lab, corroborates PMID 24098681","pmids":["25861374"],"is_preprint":false},{"year":2010,"finding":"CDKN1C interacts directly with E2F1, CDK7, and CDK9 in vivo and in vitro. CDKN1C is recruited to E2F1-regulated promoters and reduces RNA polymerase II CTD phosphorylation at Ser-2 and Ser-5 in an E2F1-dependent manner. CDKN1C blocks CDK7 and CDK9 ability to phosphorylate a GST-CTD fusion protein in vitro. The E2F1-CDKN1C interaction is mediated by two E2F1 domains.","method":"Adenoviral overexpression, RNA interference, chromatin immunoprecipitation (ChIP), in vitro kinase assay with GST-CTD, co-immunoprecipitation in vivo and in vitro","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods including in vitro kinase reconstitution, ChIP, reciprocal co-IP, siRNA knockdown with endogenous protein; single lab but rigorous","pmids":["20106982"],"is_preprint":false},{"year":2008,"finding":"miR-221 directly targets a site in the 3' UTR of CDKN1C/p57 mRNA to suppress its expression. Transfection of miR-221 into HCC-derived cells downregulates CDKN1C/p57 protein, and antimiR-221 upregulates it, promoting cell growth by increasing S-phase entry.","method":"miRNA transfection, antimiR transfection, luciferase reporter assay with 3'UTR, Western blotting, flow cytometry","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct 3'UTR reporter validation, gain and loss of function experiments, replicated in colorectal cancer (PMID 21278784)","pmids":["18521080","21278784"],"is_preprint":false},{"year":2009,"finding":"CDKN1C is a direct target of EZH2-mediated histone H3 lysine 27 trimethylation (H3K27me3) in breast cancer cells. EZH2 inhibition activates CDKN1C, synergistically enhanced by histone deacetylase inhibitor co-treatment.","method":"Chromatin immunoprecipitation (ChIP) for H3K27me3, EZH2 knockdown/inhibition, gene expression analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP demonstrating direct EZH2/H3K27me3 at CDKN1C locus, replicated in multiple cancer contexts (PMID 29632530, 31367252, 33792119)","pmids":["19340297","29632530","31367252","33792119"],"is_preprint":false},{"year":2005,"finding":"Lsh (a SNF2-family chromatin remodeling protein) directly associates with the 5' differentially methylated region (DMR) at the Cdkn1c promoter by ChIP and controls CpG methylation at this DMR, specifically silencing the paternal Cdkn1c allele. Loss of Lsh reactivates the silenced paternal allele correlating with loss of 5'DMR methylation, without affecting KvDMR1 or other imprinted loci.","method":"Chromatin immunoprecipitation (ChIP), allele-specific expression analysis, bisulfite sequencing of CpG methylation in Lsh-deficient mice","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct ChIP showing Lsh at Cdkn1c 5'DMR, allele-specific expression in KO model with methylation analysis; multiple orthogonal methods","pmids":["15647320"],"is_preprint":false},{"year":2004,"finding":"The differentially methylated region (DMR) associated with mouse Cdkn1c is a CpG island beginning 600 bp 5' of the promoter. This methylation is not inherited from sperm but is acquired specifically on the paternal allele after implantation, is dependent on KvDMR1, and is required for maintaining but not establishing monoallelic Cdkn1c expression.","method":"Bisulfite sequencing, methylation analysis of gametes and postimplantation embryos, analysis of KvDMR1-deletion mouse model","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic analysis across developmental stages with KvDMR1-dependent genetic dissection; multiple orthogonal methods in single rigorous study","pmids":["15533713"],"is_preprint":false},{"year":2005,"finding":"ZAC (a sequence-specific DNA-binding protein) binds within the CpG island of LIT1 (KCNQ1OT1) and induces LIT1 transcription in a methylation-dependent manner, suggesting ZAC regulates p57KIP2 (CDKN1C) through LIT1 in a novel imprinted gene network.","method":"DNA-binding assays, transfection reporter assays, methylation-dependent transcription assays","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct DNA-binding assay and transcriptional reporter, but the ZAC→LIT1→CDKN1C pathway is partially indirect; single lab","pmids":["15888726"],"is_preprint":false},{"year":2001,"finding":"Enhancers for Cdkn1c expression in skeletal muscle and cartilage lie more than 25 kb downstream of the gene, demonstrating distant cis-regulation. BAC transgenes spanning 315 kb showed no allele-specific expression, suggesting the key imprinting element also lies at a distance from the gene.","method":"Bacterial artificial chromosome (BAC) transgenic mouse models, tissue-specific expression analysis","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic BAC experiments directly establish cis-regulatory distance; single lab, clean genetic approach","pmids":["11468278"],"is_preprint":false},{"year":2007,"finding":"Cdkn1c is the major regulator of embryonic growth within its IC2 imprinted domain in mice. Excess Cdkn1c (via BAC transgene copy number) causes dosage-dependent embryonic growth retardation and lethality associated with reduced Igf1 expression. Loss of Cdkn1c results in 11% heavier embryos with 2-fold increase in Igf1.","method":"BAC transgenic mouse models with varying copy numbers, embryonic weight measurements, gene expression analysis","journal":"BMC developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — dosage-response genetic experiment in mice with multiple copy number integrations and reciprocal loss-of-function; well-controlled mechanistic study","pmids":["17517131"],"is_preprint":false},{"year":2011,"finding":"Cdkn1c mutant mouse embryos exhibit 20% overgrowth during gestation but experience growth reversal late in gestation. Cdkn1c deficiency causes marked placental dysfunction including thrombotic lesions in the labyrinth zone, loss of sinusoidal giant cells, and disordered trilaminar trophoblast layer, identifying a role for Cdkn1c in maintaining the maternal-fetal interface.","method":"Mouse genetic model, placental histology, embryonic weight analysis","journal":"Disease models & mechanisms","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined cellular phenotype in KO model with specific placental histological readouts; single lab","pmids":["21729874"],"is_preprint":false},{"year":2003,"finding":"Loss of maternal methylation (LOM) at KvDMR1 in BWS patients causes an 86-93% reduction in CDKN1C expression in fibroblast cells approximately 180 kb away on the maternal chromosome, without hypermethylation at the CDKN1C promoter itself.","method":"Quantitative PCR, ribonuclease protection assay, Southern hybridization with methylation-sensitive restriction endonuclease","journal":"Journal of medical genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — two orthogonal quantitative assays (qPCR + RPA) confirming dramatic expression loss, with promoter methylation ruled out by Southern analysis; replicated in human patient samples","pmids":["14627666"],"is_preprint":false},{"year":2013,"finding":"ARX is a direct transcriptional repressor of CDKN1C in cortical progenitor cells. Loss of cortical ARX results in overexpression of CDKN1C, reduced intermediate progenitor cell (IPC) proliferation, and a reduction in upper-layer neurons.","method":"Conditional knockout mouse model (cortex-specific Arx cKO), transcriptional profiling, chromatin immunoprecipitation (ChIP) for ARX at Cdkn1c promoter, cortical cell counting","journal":"Cerebral cortex","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO model with defined neuronal phenotype plus direct ChIP demonstration of ARX at Cdkn1c; multiple orthogonal methods","pmids":["23968833"],"is_preprint":false},{"year":2012,"finding":"CDKN1C is a downstream transcriptional target of SMARCB1 and is activated by increased histone H3 and H4 acetylation at its promoter. CDKN1C expression induces cell cycle arrest in rhabdoid tumor cells; siRNA knockdown of CDKN1C increases proliferation and competes against the anti-proliferative effect of restored SMARCB1. The HDAC inhibitor Romidepsin specifically restores CDKN1C expression through promoter histone acetylation.","method":"Inducible SMARCB1 expression system, siRNA knockdown, ChIP for histone H3/H4 acetylation at CDKN1C promoter, flow cytometry cell cycle analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including ChIP, inducible expression, siRNA rescue; specific mechanistic pathway established","pmids":["19221586"],"is_preprint":false},{"year":2018,"finding":"Targeted demethylation of imprinting control region 2 (ICR2) using a TALE-TET1 fusion protein (ICR2-TET1) reduces CDKN1C/p57 expression and increases proliferation in human fibroblasts and islets. Human islets overexpressing ICR2-TET1 show repressed p57 with upregulated Ki-67 while maintaining glucose-sensing functionality; transplanted epigenetically edited islets show increased β cell replication in diabetic mice.","method":"Epigenetic editing with TALE-TET1 fusion, cell proliferation assays, Ki-67 staining, transplantation into diabetic immunodeficient mice","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct epigenetic editing experiment with functional in vivo transplantation validation; multiple orthogonal readouts","pmids":["30352048"],"is_preprint":false},{"year":2018,"finding":"Cdkn1c is not expressed in quiescent muscle stem cells (MuSCs) but is induced in activated/proliferating myoblasts and maintained in differentiating myogenic cells. Cdkn1c subcellular localization is dynamic: initially cytoplasmic in activated/proliferating myoblasts, then progressively nuclear during differentiation to enforce growth arrest. Cdkn1c-deficient primary myoblasts display differentiation defects and increased proliferation.","method":"Mouse molecular genetics (conditional KO), live-cell imaging, subcellular fractionation, immunofluorescence, primary myoblast culture assays","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct imaging of dynamic subcellular localization tied to functional differentiation outcomes; genetic KO with defined phenotype; multiple orthogonal methods","pmids":["30284969"],"is_preprint":false},{"year":2010,"finding":"Cdkn1c is induced by Hedgehog signaling in slow muscle precursor cells in zebrafish and cooperates with Myod to drive terminal differentiation of multiple early muscle fiber types. Myod in turn upregulates cdkn1c, forming a positive feedback loop that switches myogenic cells to terminal differentiation. Neither Hedgehog nor Cdkn1c is required for cell cycle exit per se.","method":"Zebrafish genetic analysis, morpholino knockdown, immunostaining, in situ hybridization, epistasis analysis","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in zebrafish model with multiple orthogonal methods establishing pathway position; positive feedback loop experimentally demonstrated","pmids":["21147088"],"is_preprint":false},{"year":2005,"finding":"Cdkn1c is a downstream target of MyoD during myogenic differentiation in C2C12 cells. MyoD-silenced clones show altered Cdkn1c expression, and bioinformatic and functional promoter studies demonstrate Cdkn1c dependence on MyoD activity.","method":"MyoD-silenced C2C12 clone generation, cDNA microarray, promoter functional analysis, quantitative PCR","journal":"Journal of molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional promoter analysis combined with microarray and MyoD-KD; single lab","pmids":["15890200"],"is_preprint":false},{"year":2015,"finding":"Paternal allelic mutation at the Kcnq1 locus reduces Kcnq1ot1 expression and increases Cdkn1c expression specifically on the paternal allele, reducing pancreatic β-cell mass. Histone modifications at the Cdkn1c promoter region in pancreatic islets contribute to this epigenetic regulation.","method":"Genetically modified mice (paternal vs maternal transmission), quantitative RT-PCR, histone modification ChIP in pancreatic islets, β-cell mass measurements","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — parent-of-origin genetic experiment with ChIP-verified histone modification at Cdkn1c promoter and functional β-cell mass phenotype; multiple orthogonal methods","pmids":["26100882"],"is_preprint":false},{"year":2016,"finding":"Cdkn1c is required for development of the brown adipose lineage. Loss-of-function of Cdkn1c results in complete developmental failure of the brown adipocyte lineage. Cdkn1c is required for post-transcriptional accumulation of the brown fat determinant PRDM16, and CDKN1C and PRDM16 co-localize to the nucleus of rare label-retaining cells within interscapular brown adipose tissue.","method":"Mouse genetic models (gain and loss of function Cdkn1c), brown adipose tissue histology, immunostaining, ex vivo differentiation assays, co-localization imaging","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal gain/loss-of-function genetics with specific mechanistic link to PRDM16 protein stabilization; multiple orthogonal methods","pmids":["26963625"],"is_preprint":false},{"year":2020,"finding":"Cdkn1c has a cell-autonomous growth-promoting function in radial glial progenitor cells and nascent projection neurons in the cerebral cortex, mediating their survival. This is distinct from its non-cell-autonomous growth-inhibitory function. The growth-promoting function is dosage-sensitive but not subject to genomic imprinting.","method":"Mosaic Analysis with Double Markers (MADM) technology for single-cell resolution genetic dissection, cell counting, clonal analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — MADM provides single-cell resolution dissection of cell-autonomous vs non-cell-autonomous functions; rigorous genetic method with defined cellular phenotype","pmids":["31924768"],"is_preprint":false},{"year":2019,"finding":"CDYL recruits EZH2 to the CDKN1C promoter region to regulate H3K27 trimethylation, causing transcriptional silencing of CDKN1C and promoting chemoresistance in small cell lung cancer. The CDYL/EZH2/CDKN1C axis was established by ChIP-qPCR, co-immunoprecipitation, GST pull-down, and EMSA assays.","method":"ChIP-qPCR, co-immunoprecipitation, GST pull-down, EMSA, mRNA sequencing, Western blotting, in vivo tumor models","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (ChIP, Co-IP, GST pulldown, EMSA) directly establishing CDYL-EZH2 interaction at CDKN1C promoter; in vitro and in vivo validation","pmids":["31367252"],"is_preprint":false},{"year":2017,"finding":"Acute exposure to chromatin-modifying drugs causes temporary de-repression of the paternal (silent) Cdkn1c allele in mouse embryos. Chronic in utero maternal dietary protein deprivation causes permanent de-repression of imprinted Cdkn1c expression through a folate-dependent mechanism of DNA methylation loss at the paternal allele, sustained into adulthood.","method":"Allele-specific bioluminescent reporters (Cdkn1c-luciferase mice), in vivo live imaging, DNA methylation analysis, dietary manipulation studies","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct non-invasive allele-specific reporter system in vivo, mechanistic link to folate/DNA methylation established with multiple orthogonal assays","pmids":["28147266"],"is_preprint":false},{"year":2020,"finding":"The paternal allele of Cdkn1c is expressed at a low level in the developing mouse neocortex. CNS-specific conditional deletion of the paternal allele results in marked reduction in brain size and reduction in neural stem-progenitor cell (NPC) number during neocortical development, reducing upper-layer neuron production.","method":"Conditional allele-specific KO mice (CNS-Cre for paternal allele), brain size measurement, immunostaining, NPC counting","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct genetic dissection of paternal allele-specific function with defined cellular phenotype; single lab","pmids":["32024956"],"is_preprint":false},{"year":2023,"finding":"IGF2 promotes terminal differentiation of neural stem cells (NSCs) into astrocytes, neurons, and oligodendrocytes by inducing Cdkn1c/p57 expression. Using intraventricular infusion of recombinant IGF2 in Cdkn1c-deficient NSC conditional mutants, p57 was confirmed to partially mediate IGF2's differentiation effects independently of its role in cell-cycle progression.","method":"Conditional KO of Cdkn1c in NSCs, intraventricular infusion of recombinant IGF2, lineage analysis, genetic epistasis","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with conditional KO combined with recombinant protein rescue; established pathway position of CDKN1C downstream of IGF2 in NSC differentiation","pmids":["36633189"],"is_preprint":false},{"year":2013,"finding":"CDKN1C mutation p.Arg279Leu in the PCNA-binding domain causes familial RSS phenotype. Functional analysis showed this mutation did not affect the cell cycle (unlike IMAGe mutations), but led to increased CDKN1C protein stability. The IMAGe mutation p.Arg279Pro caused gain-of-function cell cycle effects.","method":"Flow cytometry cell cycle analysis, Western blotting with cycloheximide to assess stability, Sanger sequencing","journal":"Journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional assays (cell cycle, protein stability) distinguishing RSS from IMAGe mutations; single lab","pmids":["24065356"],"is_preprint":false},{"year":2017,"finding":"Cdkn1c elevated expression in the brain (in a transgenic loss-of-imprinting model) leads to altered dopaminergic gene expression, increased tyrosine hydroxylase staining, and increased dopamine tissue content in the striatum, indicating a functional role for Cdkn1c dosage in midbrain dopaminergic neuron development and behavior.","method":"Cdkn1c BAC transgenic (Cdkn1cBACx1) mouse model, tyrosine hydroxylase immunostaining, HPLC dopamine quantification, c-fos expression, behavioral assays","journal":"Genes, brain, and behavior","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined cellular and behavioral phenotype in transgenic model with multiple neurochemical readouts; single lab","pmids":["28857482"],"is_preprint":false},{"year":2012,"finding":"Hes1 (a Notch effector) directly represses CDKN1C/P57 transcription in hepatocellular carcinoma cells. Downregulation of Notch1/3 leads to Hes1 downregulation and CDKN1C/P57 upregulation. CDKN1C/P57 upregulation induces cellular senescence (senescence-associated β-galactosidase accumulation, P16 increase, morphological changes) without affecting apoptosis.","method":"siRNA knockdown of Notch1/Notch3/Hes1, cDNA transfection of CDKN1C, flow cytometry, senescence-associated β-galactosidase assay, Western blotting","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional pathway dissection with genetic epistasis (Hes1/CDKN1C double depletion confirming senescence dependence on CDKN1C); single lab","pmids":["22705236"],"is_preprint":false},{"year":2019,"finding":"miR-222 derived from M1 macrophage exosomes promotes vascular smooth muscle cell (VSMC) proliferation and migration by targeting CDKN1C (and CDKN1B). These exosomes are taken up by VSMCs through macropinocytosis, and miR-222 inhibitor abolishes this effect in vitro and in vivo.","method":"Transwell co-culture, exosome isolation, microRNA array, luciferase reporter assay for 3'UTR targeting, carotid artery ligation model, miR-222 inhibitor treatment","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — 3'UTR direct targeting validated by reporter assay, in vitro and in vivo functional confirmation; single lab","pmids":["31142732"],"is_preprint":false},{"year":2018,"finding":"Ezh2 represses Cdkn1c (and Cdkn2a) in activated naive CD8+ T cells by H3K27me3 at these gene loci. Deletion of Ezh2 in CD8+ T cells increases Cdkn1c and Cdkn2a expression and impairs activation-induced proliferation with prolonged cell division times.","method":"Conditional Ezh2 KO mice (Ezh2fl/fl Cd4Cre+ and GzmBCre+), ChIP for H3K27me3, quantitative PCR, real-time live imaging of cell division","journal":"Frontiers in immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP directly demonstrating H3K27me3 at Cdkn1c locus in Ezh2 KO T cells, two conditional KO models dissecting temporal requirements, live imaging readout","pmids":["29632530"],"is_preprint":false},{"year":2021,"finding":"MBD2 (a DNA methylation reader) promotes leukemic stem cell (LSC) cycle progression through epigenetic regulation of CDKN1C transcription by binding to its promoter region. Loss of MBD2 delays MLL-AF9-driven leukemia initiation and progression via increased CDKN1C expression.","method":"MBD2 knockout in MLL-AF9 murine leukemia model, serial transplantation, gene expression analysis, bioinformatics, MBD2 ChIP at CDKN1C promoter","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO model with defined leukemia phenotype and ChIP evidence for MBD2 binding at CDKN1C promoter; single lab","pmids":["34789717"],"is_preprint":false},{"year":2015,"finding":"miR-25 directly targets the 3'UTR of CDKN1C to reduce its protein levels, increasing glioma cell proliferation. Ablation of endogenous miR-25 rescues CDKN1C expression and decreases glioma cell proliferation. Downregulation of CDKN1C by siRNA blocked the antiproliferative activity of miR-25 inhibition.","method":"3'UTR luciferase reporter assay, miR-25 overexpression/knockdown, siRNA, cell proliferation assays, flow cytometry","journal":"Biomedicine & pharmacotherapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct 3'UTR reporter assay with functional rescue by siRNA; single lab","pmids":["25960208"],"is_preprint":false},{"year":2017,"finding":"The T2DM-associated SNP rs163184 in the KCNQ1 intronic region modulates binding of Sp3 and Lsd1/Kdm1a in an allele-specific manner. Sp3 binds preferentially to the non-risk allele and stimulates transcriptional activity. Lsd1/Kdm1a is preferentially recruited to the non-risk allele and reduces Sp3-dependent transcriptional activity. SP3 knockdown upregulates CDKN1C expression in cells with non-risk alleles.","method":"DNA pulldown with allele-specific probes, mass spectrometry protein identification, artificial promoter reporter assay, SP3 siRNA knockdown, gene expression analysis","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — allele-specific protein binding and functional promoter assays; indirect link to CDKN1C through SP3; single lab","pmids":["29207083"],"is_preprint":false},{"year":2016,"finding":"CTCF binding sites are present within the unmethylated CDKN1C gene body CpG island in human placenta. Putative enhancer regions containing H3K4me1 and H3K27ac marks are located approximately 58 and 360 kb from CDKN1C. 3C-PCR identifies constitutive higher-order chromatin loops between one of these enhancer regions and CDKN1C in human placenta.","method":"Chromatin immunoprecipitation (ChIP) for CTCF and histone marks, Chromosome Conformation Capture (3C-PCR)","journal":"Frontiers in genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP and 3C-PCR demonstrating CTCF binding and chromatin loops; single lab, focused on placenta","pmids":["27200075"],"is_preprint":false}],"current_model":"CDKN1C/p57KIP2 is a maternally expressed, imprinted cyclin-dependent kinase inhibitor whose expression is controlled by KvDMR1/ICR2 methylation and multiple epigenetic mechanisms including EZH2/EZH1-mediated H3K27me3, Lsh-dependent CpG methylation at its 5' DMR, and SMARCB1-dependent histone acetylation; it inhibits cell-cycle progression by binding cyclin/CDK complexes, suppressing RNA polymerase II CTD phosphorylation via E2F1-directed recruitment to inhibit CDK7/CDK9, and its PCNA-binding domain regulates protein stability (loss of PCNA binding stabilizes the protein causing gain-of-function growth restriction in IMAGe syndrome, while loss-of-function causes overgrowth in Beckwith-Wiedemann syndrome); beyond cell-cycle arrest, CDKN1C plays cell-autonomous roles in radial glial progenitor survival, myoblast differentiation (via cytoplasmic-to-nuclear translocation), brown adipose tissue development (promoting PRDM16 accumulation), and dopaminergic neuron function, and is regulated post-transcriptionally by multiple miRNAs (miR-221, miR-25, miR-222, miR-199a-5p) targeting its 3'UTR."},"narrative":{"mechanistic_narrative":"CDKN1C/p57KIP2 is a maternally expressed, imprinted cyclin-dependent kinase inhibitor that restrains cell proliferation and controls embryonic and tissue growth in a strictly dosage-sensitive manner [PMID:17517131]. Its expression is set by a layered epigenetic architecture: imprinted silencing of the paternal allele depends on a 5' differentially methylated region whose CpG methylation is acquired after implantation under control of the distal KvDMR1/ICR2 and enforced by the chromatin remodeler Lsh [PMID:15533713, PMID:15647320], while regulation also occurs over long distances through enhancers and CTCF-anchored chromatin loops tens to hundreds of kilobases from the gene [PMID:11468278, PMID:27200075]; loss of maternal KvDMR1 methylation collapses CDKN1C expression in cis without altering the promoter itself [PMID:14627666]. Beyond imprinting, CDKN1C transcription is gated by Polycomb EZH2/H3K27me3 — recruited via partners such as CDYL — and by SMARCB1-dependent promoter histone acetylation, and is repressed by transcription factors including ARX and the Notch effector Hes1, the latter coupling CDKN1C induction to cellular senescence [PMID:19340297, PMID:29632530, PMID:31367252, PMID:33792119, PMID:19221586, PMID:23968833, PMID:22705236]. Mechanistically, CDKN1C is recruited to E2F1-regulated promoters where it binds E2F1, CDK7 and CDK9 and suppresses RNA polymerase II CTD phosphorylation at Ser-2 and Ser-5, directly linking it to transcriptional control of the cell cycle [PMID:20106982]. Its activity is tuned post-transcriptionally by proteasomal turnover gated through a PCNA-binding domain and by 3'UTR-targeting miRNAs (miR-221, miR-25, miR-222) [PMID:24098681, PMID:25861374, PMID:18521080, PMID:21278784, PMID:25960208, PMID:31142732]. Mutations in the PCNA-binding domain that abolish PCNA binding stabilize the protein and produce a gain-of-function growth-restriction phenotype causing IMAGe syndrome, distinct from loss-of-function overgrowth, with a related stabilizing mutation underlying a familial Russell-Silver phenotype [PMID:22634751, PMID:24098681, PMID:25861374, PMID:24065356]. CDKN1C also carries growth-restricting and, separately, cell-autonomous growth-promoting/survival roles in defined lineages: it enforces myoblast differentiation through dynamic cytoplasmic-to-nuclear translocation and a MyoD feedback loop, drives terminal differentiation of neural stem cells downstream of IGF2, supports radial glial progenitor survival, and is required for brown adipose development via post-transcriptional accumulation of PRDM16 [PMID:30284969, PMID:21147088, PMID:36633189, PMID:31924768, PMID:26963625].","teleology":[{"year":2004,"claim":"Established that monoallelic CDKN1C expression depends on a post-implantation-acquired 5' DMR methylation mark rather than a gamete-inherited one, redefining how the imprint is maintained.","evidence":"Bisulfite sequencing across gametes and embryos plus KvDMR1-deletion mouse analysis","pmids":["15533713"],"confidence":"High","gaps":["Does not identify the enzymes that acquire the paternal methylation","Mechanism by which KvDMR1 directs the distal mark unresolved"]},{"year":2005,"claim":"Identified the chromatin remodeler Lsh as a direct effector that establishes 5'DMR CpG methylation to silence the paternal allele, providing a molecular actor for the imprint.","evidence":"ChIP, allele-specific expression and bisulfite sequencing in Lsh-deficient mice","pmids":["15647320"],"confidence":"High","gaps":["How Lsh is targeted specifically to the paternal 5'DMR unknown","Relationship to KvDMR1 control not fully defined"]},{"year":2003,"claim":"Showed that loss of maternal KvDMR1 methylation in BWS patients reduces CDKN1C expression by >85% from ~180 kb away without promoter hypermethylation, linking a distal imprinting defect to disease through long-range cis regulation.","evidence":"qPCR, RNase protection and methylation-sensitive Southern in patient fibroblasts","pmids":["14627666"],"confidence":"High","gaps":["Physical mechanism connecting KvDMR1 to CDKN1C silencing not shown","Cell-type specificity beyond fibroblasts not addressed"]},{"year":2007,"claim":"Demonstrated that CDKN1C is the dominant dosage-sensitive growth regulator of its imprinted domain, with bidirectional effects on embryo size linked to Igf1.","evidence":"BAC transgenic copy-number series and reciprocal loss-of-function in mice","pmids":["17517131"],"confidence":"High","gaps":["Direct molecular link between CDKN1C and Igf1 not defined","Tissue origin of growth effect not localized"]},{"year":2010,"claim":"Revealed a transcriptional mechanism beyond classical CDK inhibition: CDKN1C is recruited to E2F1 promoters and suppresses Pol II CTD phosphorylation by inhibiting CDK7 and CDK9.","evidence":"In vivo/in vitro co-IP, ChIP, siRNA, and in vitro GST-CTD kinase assays","pmids":["20106982"],"confidence":"High","gaps":["Genome-wide scope of E2F1-directed recruitment unknown","Physiological contexts where this dominates over cyclin/CDK inhibition unclear"]},{"year":2012,"claim":"Defined the molecular basis of IMAGe syndrome as gain-of-function PCNA-binding-domain mutations distinct from BWS loss-of-function, establishing a domain-specific genotype-phenotype split.","evidence":"IBD mapping, exon sequencing, and Drosophila transgenic overexpression","pmids":["22634751"],"confidence":"High","gaps":["Cellular mechanism of gain-of-function not yet explained in this study","Role of PCNA binding in normal regulation undefined here"]},{"year":2013,"claim":"Explained the IMAGe gain-of-function as impaired proteasomal degradation via loss of PCNA binding, identifying protein stability as a key regulatory node.","evidence":"Cycloheximide chase, MG132 rescue and PCNA co-IP; replicated independently","pmids":["24098681","25861374"],"confidence":"High","gaps":["E3 ligase mediating PCNA-dependent turnover not identified","Whether PCNA binding directly couples to degradation machinery unresolved"]},{"year":2013,"claim":"Distinguished a related familial Russell-Silver-causing PCNA-domain mutation that stabilizes protein without altering the cell cycle, refining the allelic-series model.","evidence":"Cell-cycle flow cytometry, cycloheximide stability assay and Sanger sequencing","pmids":["24065356"],"confidence":"Medium","gaps":["Single lab; mechanism distinguishing RSS from IMAGe phenotypically not fully resolved","How stability without cell-cycle change produces growth restriction unclear"]},{"year":2009,"claim":"Placed CDKN1C under Polycomb control, showing EZH2/H3K27me3 directly silences it and is reversible by combined EZH2 and HDAC inhibition.","evidence":"ChIP for H3K27me3 with EZH2 knockdown/inhibition; replicated across cancers","pmids":["19340297","29632530","31367252","33792119"],"confidence":"High","gaps":["Recruitment specificity of EZH2 to the locus not addressed here","Interaction with imprinting machinery unclear"]},{"year":2019,"claim":"Identified CDYL as a recruiter of EZH2 to the CDKN1C promoter, supplying a targeting mechanism for Polycomb silencing linked to chemoresistance.","evidence":"ChIP-qPCR, co-IP, GST pull-down, EMSA and in vivo tumor models","pmids":["31367252"],"confidence":"High","gaps":["Generality of CDYL-dependent recruitment beyond SCLC unknown","Signals controlling CDYL engagement undefined"]},{"year":2012,"claim":"Connected SMARCB1/SWI-SNF to CDKN1C activation through promoter histone acetylation, establishing a tumor-suppressor axis in rhabdoid tumors.","evidence":"Inducible SMARCB1, siRNA rescue, acetylation ChIP and cell-cycle analysis","pmids":["19221586"],"confidence":"High","gaps":["Direct vs indirect SMARCB1 action at the promoter not fully separated","Interplay with Polycomb silencing not tested"]},{"year":2013,"claim":"Showed ARX directly represses CDKN1C in cortical progenitors, tying its dosage to intermediate progenitor proliferation and neuronal output.","evidence":"Cortex-specific Arx cKO, expression profiling and ChIP at the promoter","pmids":["23968833"],"confidence":"High","gaps":["Whether repression is direct transcriptional or context-dependent not fully resolved","Cofactors of ARX at the locus unknown"]},{"year":2008,"claim":"Established post-transcriptional control of CDKN1C by miR-221 acting on its 3'UTR, linking miRNA dysregulation to proliferative phenotypes.","evidence":"miR/antimiR transfection, 3'UTR luciferase reporter, Western and flow cytometry; replicated","pmids":["18521080","21278784"],"confidence":"High","gaps":["Relative contribution versus transcriptional control in vivo unclear","Tissue-specific miRNA regulation not mapped"]},{"year":2018,"claim":"Demonstrated dynamic cytoplasmic-to-nuclear translocation of CDKN1C as the switch enforcing myoblast growth arrest and differentiation.","evidence":"Conditional KO, live imaging, subcellular fractionation and primary myoblast assays","pmids":["30284969"],"confidence":"High","gaps":["Signals driving the localization switch not identified","Cytoplasmic function molecular targets undefined"]},{"year":2010,"claim":"Positioned Cdkn1c in a Hedgehog-Myod positive-feedback loop driving terminal muscle differentiation independent of cell-cycle exit.","evidence":"Zebrafish genetic epistasis, morpholino knockdown and in situ analysis","pmids":["21147088"],"confidence":"High","gaps":["Molecular basis of cell-cycle-independent differentiation role unresolved","Conservation of the loop in mammals not tested here"]},{"year":2016,"claim":"Identified a lineage-specific role in which Cdkn1c is required for brown adipose development through post-transcriptional accumulation of PRDM16.","evidence":"Reciprocal gain/loss-of-function mice, BAT histology and co-localization imaging","pmids":["26963625"],"confidence":"High","gaps":["Mechanism by which CDKN1C stabilizes PRDM16 not defined","Whether nuclear co-localization is required mechanistically unclear"]},{"year":2020,"claim":"Resolved a cell-autonomous, non-imprinted growth-promoting/survival function of Cdkn1c in radial glial progenitors, opposite to its non-cell-autonomous inhibitory role.","evidence":"MADM single-cell-resolution clonal genetic analysis","pmids":["31924768"],"confidence":"High","gaps":["Molecular pathway of the pro-survival function unknown","How a CDK inhibitor promotes growth mechanistically unexplained"]},{"year":2023,"claim":"Placed Cdkn1c downstream of IGF2 as a partial mediator of neural stem cell terminal differentiation, separating its differentiation role from cell-cycle control.","evidence":"Conditional Cdkn1c KO with recombinant IGF2 infusion and lineage epistasis","pmids":["36633189"],"confidence":"High","gaps":["Other IGF2 effectors not identified","Direct molecular link between IGF2 signaling and Cdkn1c induction unknown"]},{"year":null,"claim":"How CDKN1C's opposing cell-autonomous growth-promoting and non-cell-autonomous growth-inhibitory functions are molecularly partitioned, and which degradation machinery couples PCNA binding to turnover, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["E3 ligase for PCNA-dependent CDKN1C degradation unidentified","Mechanism of growth-promoting function uncharacterized","Integration of imprinting, Polycomb, and SWI-SNF inputs at one locus not unified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,10,2]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[16,20]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[16]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[2,3]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[10,16,17,20,21,25]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[5,6,14,22]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,13,28]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,12,26]}],"complexes":[],"partners":["PCNA","E2F1","CDK7","CDK9","PRDM16"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P49918","full_name":"Cyclin-dependent kinase inhibitor 1C","aliases":["Cyclin-dependent kinase inhibitor p57","p57Kip2"],"length_aa":316,"mass_kda":32.2,"function":"Potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to lesser extent, of the mitotic cyclin B-CDC2. Negative regulator of cell proliferation. May play a role in maintenance of the non-proliferative state throughout life","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P49918/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CDKN1C","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CDKN1C","total_profiled":1310},"omim":[{"mim_id":"618844","title":"L3MBTL HISTONE METHYL-LYSINE-BINDING PROTEIN 3; L3MBTL3","url":"https://www.omim.org/entry/618844"},{"mim_id":"618336","title":"INTRAUTERINE GROWTH RETARDATION, METAPHYSEAL DYSPLASIA, ADRENAL HYPOPLASIA CONGENITA, GENITAL ANOMALIES, AND IMMUNODEFICIENCY; IMAGEI","url":"https://www.omim.org/entry/618336"},{"mim_id":"618178","title":"NEPHROTIC SYNDROME, TYPE 19; NPHS19","url":"https://www.omim.org/entry/618178"},{"mim_id":"614732","title":"INTRAUTERINE GROWTH RETARDATION, METAPHYSEAL DYSPLASIA, ADRENAL HYPOPLASIA CONGENITA, AND GENITAL ANOMALIES; IMAGE","url":"https://www.omim.org/entry/614732"},{"mim_id":"614041","title":"RB TRANSCRIPTIONAL COREPRESSOR 1; RB1","url":"https://www.omim.org/entry/614041"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Nuclear bodies","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":191.6},{"tissue":"ovary","ntpm":188.1}],"url":"https://www.proteinatlas.org/search/CDKN1C"},"hgnc":{"alias_symbol":["P57","KIP2"],"prev_symbol":["BWCR","BWS"]},"alphafold":{"accession":"P49918","domains":[{"cath_id":"-","chopping":"79-116","consensus_level":"medium","plddt":72.7811,"start":79,"end":116},{"cath_id":"1.20.5","chopping":"36-70","consensus_level":"medium","plddt":94.8411,"start":36,"end":70}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P49918","model_url":"https://alphafold.ebi.ac.uk/files/AF-P49918-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P49918-F1-predicted_aligned_error_v6.png","plddt_mean":62.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CDKN1C","jax_strain_url":"https://www.jax.org/strain/search?query=CDKN1C"},"sequence":{"accession":"P49918","fasta_url":"https://rest.uniprot.org/uniprotkb/P49918.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P49918/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P49918"}},"corpus_meta":[{"pmid":"18521080","id":"PMC_18521080","title":"MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18521080","citation_count":527,"is_preprint":false},{"pmid":"19340297","id":"PMC_19340297","title":"CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19340297","citation_count":143,"is_preprint":false},{"pmid":"10424811","id":"PMC_10424811","title":"Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation.","date":"1999","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10424811","citation_count":139,"is_preprint":false},{"pmid":"22634751","id":"PMC_22634751","title":"Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome.","date":"2012","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22634751","citation_count":132,"is_preprint":false},{"pmid":"11181570","id":"PMC_11181570","title":"Increased tumour risk for BWS patients correlates with aberrant H19 and not KCNQ1OT1 methylation: occurrence of KCNQ1OT1 hypomethylation in familial cases of BWS.","date":"2001","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11181570","citation_count":125,"is_preprint":false},{"pmid":"14627666","id":"PMC_14627666","title":"Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome.","date":"2003","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14627666","citation_count":123,"is_preprint":false},{"pmid":"24065356","id":"PMC_24065356","title":"CDKN1C mutation affecting the PCNA-binding domain as a cause of familial Russell Silver syndrome.","date":"2013","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24065356","citation_count":104,"is_preprint":false},{"pmid":"15888726","id":"PMC_15888726","title":"ZAC, LIT1 (KCNQ1OT1) and p57KIP2 (CDKN1C) are in an imprinted gene network that may play a role in Beckwith-Wiedemann syndrome.","date":"2005","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/15888726","citation_count":103,"is_preprint":false},{"pmid":"10607831","id":"PMC_10607831","title":"Identification and characterization of MTR1, a novel gene with homology to melastatin (MLSN1) and the trp gene family located in the BWS-WT2 critical region on chromosome 11p15.5 and showing allele-specific expression.","date":"2000","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10607831","citation_count":101,"is_preprint":false},{"pmid":"8518793","id":"PMC_8518793","title":"Molecular characterization of cytogenetic alterations associated with the Beckwith-Wiedemann syndrome (BWS) phenotype refines the localization and suggests the gene for BWS is imprinted.","date":"1993","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8518793","citation_count":92,"is_preprint":false},{"pmid":"21447370","id":"PMC_21447370","title":"The hallmarks of CDKN1C (p57, KIP2) in cancer.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21447370","citation_count":91,"is_preprint":false},{"pmid":"17517131","id":"PMC_17517131","title":"Cdkn1c (p57Kip2) is the major regulator of embryonic growth within its imprinted domain on mouse distal chromosome 7.","date":"2007","source":"BMC developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17517131","citation_count":82,"is_preprint":false},{"pmid":"21278784","id":"PMC_21278784","title":"MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma.","date":"2011","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/21278784","citation_count":78,"is_preprint":false},{"pmid":"21729874","id":"PMC_21729874","title":"Fetal overgrowth in the Cdkn1c mouse model of Beckwith-Wiedemann syndrome.","date":"2011","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/21729874","citation_count":78,"is_preprint":false},{"pmid":"25262539","id":"PMC_25262539","title":"CDKN1C mutations: two sides of the same coin.","date":"2014","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25262539","citation_count":77,"is_preprint":false},{"pmid":"19513094","id":"PMC_19513094","title":"Lessons from BWS twins: complex maternal and paternal hypomethylation and a common source of haematopoietic stem cells.","date":"2009","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/19513094","citation_count":73,"is_preprint":false},{"pmid":"18212817","id":"PMC_18212817","title":"MS-MLPA is a specific and sensitive technique for detecting all chromosome 11p15.5 imprinting defects of BWS and SRS in a single-tube experiment.","date":"2008","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/18212817","citation_count":66,"is_preprint":false},{"pmid":"11454518","id":"PMC_11454518","title":"Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors.","date":"2001","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11454518","citation_count":65,"is_preprint":false},{"pmid":"11468278","id":"PMC_11468278","title":"Distant cis-elements regulate imprinted expression of the mouse p57( Kip2) (Cdkn1c) gene: implications for the human disorder, Beckwith--Wiedemann syndrome.","date":"2001","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11468278","citation_count":64,"is_preprint":false},{"pmid":"20503313","id":"PMC_20503313","title":"CDKN1C (p57(Kip2)) analysis in Beckwith-Wiedemann syndrome (BWS) patients: Genotype-phenotype correlations, novel mutations, and polymorphisms.","date":"2010","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/20503313","citation_count":62,"is_preprint":false},{"pmid":"26077438","id":"PMC_26077438","title":"Mutations of the Imprinted CDKN1C Gene as a Cause of the Overgrowth Beckwith-Wiedemann Syndrome: Clinical Spectrum and Functional Characterization.","date":"2015","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/26077438","citation_count":61,"is_preprint":false},{"pmid":"15647320","id":"PMC_15647320","title":"Lsh controls silencing of the imprinted Cdkn1c gene.","date":"2005","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15647320","citation_count":60,"is_preprint":false},{"pmid":"15533713","id":"PMC_15533713","title":"Methylation at mouse Cdkn1c is acquired during postimplantation development and functions to maintain imprinted expression.","date":"2004","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/15533713","citation_count":59,"is_preprint":false},{"pmid":"22705236","id":"PMC_22705236","title":"CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma.","date":"2012","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22705236","citation_count":58,"is_preprint":false},{"pmid":"31142732","id":"PMC_31142732","title":"Exosomes derived from M1 macrophages aggravate neointimal hyperplasia following carotid artery injuries in mice through miR-222/CDKN1B/CDKN1C pathway.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31142732","citation_count":58,"is_preprint":false},{"pmid":"15580204","id":"PMC_15580204","title":"Epigenotyping as a tool for the prediction of tumor risk and tumor type in patients with Beckwith-Wiedemann syndrome (BWS).","date":"2004","source":"The Journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/15580204","citation_count":57,"is_preprint":false},{"pmid":"29614816","id":"PMC_29614816","title":"Genetic and Epigenetic Control of CDKN1C Expression: Importance in Cell Commitment and Differentiation, Tissue Homeostasis and Human Diseases.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29614816","citation_count":55,"is_preprint":false},{"pmid":"26100882","id":"PMC_26100882","title":"Paternal allelic mutation at the Kcnq1 locus reduces pancreatic β-cell mass by epigenetic modification of Cdkn1c.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26100882","citation_count":54,"is_preprint":false},{"pmid":"23968833","id":"PMC_23968833","title":"ARX regulates cortical intermediate progenitor cell expansion and upper layer neuron formation through repression of Cdkn1c.","date":"2013","source":"Cerebral cortex (New York, N.Y. : 1991)","url":"https://pubmed.ncbi.nlm.nih.gov/23968833","citation_count":54,"is_preprint":false},{"pmid":"15551363","id":"PMC_15551363","title":"Multiple mechanisms downregulate CDKN1C in human bladder cancer.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15551363","citation_count":53,"is_preprint":false},{"pmid":"30352048","id":"PMC_30352048","title":"Targeted demethylation at the CDKN1C/p57 locus induces human β cell replication.","date":"2018","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/30352048","citation_count":52,"is_preprint":false},{"pmid":"18325103","id":"PMC_18325103","title":"CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer.","date":"2008","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18325103","citation_count":52,"is_preprint":false},{"pmid":"29632530","id":"PMC_29632530","title":"Ezh2 Regulates Activation-Induced CD8+ T Cell Cycle Progression via Repressing Cdkn2a and Cdkn1c Expression.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29632530","citation_count":51,"is_preprint":false},{"pmid":"19221586","id":"PMC_19221586","title":"Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19221586","citation_count":49,"is_preprint":false},{"pmid":"11414765","id":"PMC_11414765","title":"Imprinting status of 11p15 genes in Beckwith-Wiedemann syndrome patients with CDKN1C mutations.","date":"2001","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11414765","citation_count":47,"is_preprint":false},{"pmid":"25057881","id":"PMC_25057881","title":"A novel variant in CDKN1C is associated with intrauterine growth restriction, short stature, and early-adulthood-onset diabetes.","date":"2014","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25057881","citation_count":47,"is_preprint":false},{"pmid":"16575194","id":"PMC_16575194","title":"Imprinting disruption of the CDKN1C/KCNQ1OT1 domain: the molecular mechanisms causing Beckwith-Wiedemann syndrome and cancer.","date":"2006","source":"Cytogenetic and genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16575194","citation_count":46,"is_preprint":false},{"pmid":"30284969","id":"PMC_30284969","title":"Cellular localization of the cell cycle inhibitor Cdkn1c controls growth arrest of adult skeletal muscle stem cells.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/30284969","citation_count":42,"is_preprint":false},{"pmid":"31367252","id":"PMC_31367252","title":"CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31367252","citation_count":41,"is_preprint":false},{"pmid":"28147266","id":"PMC_28147266","title":"Visualizing Changes in Cdkn1c Expression Links Early-Life Adversity to Imprint Mis-regulation in Adults.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28147266","citation_count":40,"is_preprint":false},{"pmid":"23153226","id":"PMC_23153226","title":"Expression of KCNQ1OT1, CDKN1C, H19, and PLAGL1 and the methylation patterns at the KvDMR1 and H19/IGF2 imprinting control regions is conserved between human and bovine.","date":"2012","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/23153226","citation_count":39,"is_preprint":false},{"pmid":"24986528","id":"PMC_24986528","title":"Relevance of genomic imprinting in intrauterine human growth expression of CDKN1C, H19, IGF2, KCNQ1 and PHLDA2 imprinted genes.","date":"2014","source":"Journal of assisted reproduction and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24986528","citation_count":39,"is_preprint":false},{"pmid":"18854861","id":"PMC_18854861","title":"Determination of KCNQ1OT1 and H19 methylation levels in BWS and SRS patients using methylation-sensitive high-resolution melting analysis.","date":"2008","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/18854861","citation_count":38,"is_preprint":false},{"pmid":"33072570","id":"PMC_33072570","title":"LncRNA-BLACAT1 Facilitates Proliferation, Migration and Aerobic Glycolysis of Pancreatic Cancer Cells by Repressing CDKN1C via EZH2-Induced H3K27me3.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33072570","citation_count":37,"is_preprint":false},{"pmid":"19386358","id":"PMC_19386358","title":"CDKN1C mutations in HELLP/preeclamptic mothers of Beckwith-Wiedemann Syndrome (BWS) patients.","date":"2009","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/19386358","citation_count":37,"is_preprint":false},{"pmid":"25960208","id":"PMC_25960208","title":"miR-25 promotes glioma cell proliferation by targeting CDKN1C.","date":"2015","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/25960208","citation_count":36,"is_preprint":false},{"pmid":"33664990","id":"PMC_33664990","title":"Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells.","date":"2021","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/33664990","citation_count":36,"is_preprint":false},{"pmid":"32308561","id":"PMC_32308561","title":"Long non-coding RNA GAS5 accelerates oxidative stress in melanoma cells by rescuing EZH2-mediated CDKN1C downregulation.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/32308561","citation_count":36,"is_preprint":false},{"pmid":"21147088","id":"PMC_21147088","title":"Cdkn1c drives muscle differentiation through a positive feedback loop with Myod.","date":"2010","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/21147088","citation_count":36,"is_preprint":false},{"pmid":"7789950","id":"PMC_7789950","title":"Genome-wide loss of maternal alleles in a nephrogenic rest and Wilms' tumour from a BWS patient.","date":"1995","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7789950","citation_count":36,"is_preprint":false},{"pmid":"28421457","id":"PMC_28421457","title":"KLF15 Inhibits Cell Proliferation in Gastric Cancer Cells via Up-Regulating CDKN1A/p21 and CDKN1C/p57 Expression.","date":"2017","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28421457","citation_count":35,"is_preprint":false},{"pmid":"24098681","id":"PMC_24098681","title":"Increased protein stability of CDKN1C causes a gain-of-function phenotype in patients with IMAGe syndrome.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24098681","citation_count":33,"is_preprint":false},{"pmid":"25588980","id":"PMC_25588980","title":"Inhibition of MiR-199a-5p reduced cell proliferation in autosomal dominant polycystic kidney disease through targeting CDKN1C.","date":"2015","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/25588980","citation_count":32,"is_preprint":false},{"pmid":"31924768","id":"PMC_31924768","title":"Imprinted Cdkn1c genomic locus cell-autonomously promotes cell survival in cerebral cortex development.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31924768","citation_count":31,"is_preprint":false},{"pmid":"17351341","id":"PMC_17351341","title":"Role of the CDKN1A/p21, CDKN1C/p57, and CDKN2A/p16 genes in the risk of atherosclerosis and myocardial infarction.","date":"2007","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/17351341","citation_count":31,"is_preprint":false},{"pmid":"22205991","id":"PMC_22205991","title":"An 11p15 imprinting centre region 2 deletion in a family with Beckwith Wiedemann syndrome provides insights into imprinting control at CDKN1C.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22205991","citation_count":31,"is_preprint":false},{"pmid":"24817929","id":"PMC_24817929","title":"Expression profiling of long noncoding RNAs and the dynamic changes of lncRNA-NR024118 and Cdkn1c in angiotensin II-treated cardiac fibroblasts.","date":"2014","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24817929","citation_count":29,"is_preprint":false},{"pmid":"18510768","id":"PMC_18510768","title":"Evolution of the CDKN1C-KCNQ1 imprinted domain.","date":"2008","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/18510768","citation_count":29,"is_preprint":false},{"pmid":"19843502","id":"PMC_19843502","title":"A case of Beckwith-Wiedemann syndrome caused by a cryptic 11p15 deletion encompassing the centromeric imprinted domain of the BWS locus.","date":"2009","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19843502","citation_count":27,"is_preprint":false},{"pmid":"24704790","id":"PMC_24704790","title":"Methylation analysis in tongue tissue of BWS patients identifies the (EPI)genetic cause in 3 patients with normal methylation levels in blood.","date":"2014","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24704790","citation_count":27,"is_preprint":false},{"pmid":"15890200","id":"PMC_15890200","title":"The Ankrd2, Cdkn1c and calcyclin genes are under the control of MyoD during myogenic differentiation.","date":"2005","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15890200","citation_count":26,"is_preprint":false},{"pmid":"26963625","id":"PMC_26963625","title":"Cdkn1c Boosts the Development of Brown Adipose Tissue in a Murine Model of Silver Russell Syndrome.","date":"2016","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26963625","citation_count":25,"is_preprint":false},{"pmid":"25979571","id":"PMC_25979571","title":"Losartan reverses the down-expression of long noncoding RNA-NR024118 and Cdkn1c induced by angiotensin II in adult rat cardiac fibroblasts.","date":"2015","source":"Pathologie-biologie","url":"https://pubmed.ncbi.nlm.nih.gov/25979571","citation_count":24,"is_preprint":false},{"pmid":"27200075","id":"PMC_27200075","title":"Epigenetic Characterization of CDKN1C in Placenta Samples from Non-syndromic Intrauterine Growth Restriction.","date":"2016","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27200075","citation_count":24,"is_preprint":false},{"pmid":"7534105","id":"PMC_7534105","title":"A constitutional BWS-related t(11;16) chromosome translocation occurring in the same region of chromosome 16 implicated in Wilms' tumors.","date":"1995","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/7534105","citation_count":23,"is_preprint":false},{"pmid":"23171462","id":"PMC_23171462","title":"The role of AHI1 and CDKN1C in cutaneous T-cell lymphoma progression.","date":"2012","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/23171462","citation_count":22,"is_preprint":false},{"pmid":"15234339","id":"PMC_15234339","title":"Searching for genomic variants in IGF2 and CDKN1C in Silver-Russell syndrome patients.","date":"2004","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15234339","citation_count":22,"is_preprint":false},{"pmid":"9441738","id":"PMC_9441738","title":"Novel transcribed sequences within the BWS/WT2 region in 11p15.5: tissue-specific expression correlates with cancer type.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9441738","citation_count":22,"is_preprint":false},{"pmid":"37212524","id":"PMC_37212524","title":"PIK3R3 is upregulated in liver cancer and activates Akt signaling to control cancer growth by regulation of CDKN1C and SMC1A.","date":"2023","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37212524","citation_count":20,"is_preprint":false},{"pmid":"28857482","id":"PMC_28857482","title":"Dopaminergic and behavioural changes in a loss-of-imprinting model of Cdkn1c.","date":"2017","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/28857482","citation_count":20,"is_preprint":false},{"pmid":"32679543","id":"PMC_32679543","title":"lncRNA STEAP3-AS1 Modulates Cell Cycle Progression via Affecting CDKN1C Expression through STEAP3 in Colon Cancer.","date":"2020","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/32679543","citation_count":20,"is_preprint":false},{"pmid":"31565482","id":"PMC_31565482","title":"Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57CDKN1C and TP53INP1 in mantle cell lymphoma.","date":"2019","source":"Cancer biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31565482","citation_count":20,"is_preprint":false},{"pmid":"20106982","id":"PMC_20106982","title":"CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20106982","citation_count":20,"is_preprint":false},{"pmid":"23894493","id":"PMC_23894493","title":"Knockdown of CDKN1C (p57(kip2)) and PHLDA2 results in developmental changes in bovine pre-implantation embryos.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23894493","citation_count":19,"is_preprint":false},{"pmid":"33792119","id":"PMC_33792119","title":"CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/33792119","citation_count":19,"is_preprint":false},{"pmid":"10862080","id":"PMC_10862080","title":"Analysis of CDKN1C in Beckwith Wiedemann syndrome.","date":"2000","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/10862080","citation_count":19,"is_preprint":false},{"pmid":"25861374","id":"PMC_25861374","title":"Mutations in the PCNA-binding site of CDKN1C inhibit cell proliferation by impairing the entry into S phase.","date":"2015","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/25861374","citation_count":19,"is_preprint":false},{"pmid":"31497289","id":"PMC_31497289","title":"Analysis of CDKN1C in fetal growth restriction and pregnancy loss.","date":"2019","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/31497289","citation_count":18,"is_preprint":false},{"pmid":"36633189","id":"PMC_36633189","title":"IGF2 interacts with the imprinted gene Cdkn1c to promote terminal differentiation of neural stem cells.","date":"2023","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/36633189","citation_count":18,"is_preprint":false},{"pmid":"10424812","id":"PMC_10424812","title":"CDKN1C expression in Beckwith-Wiedemann syndrome patients with allele imbalance.","date":"1999","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10424812","citation_count":18,"is_preprint":false},{"pmid":"20372090","id":"PMC_20372090","title":"Autonomous silencing of the imprinted Cdkn1c gene in stem cells.","date":"2010","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/20372090","citation_count":17,"is_preprint":false},{"pmid":"16061564","id":"PMC_16061564","title":"Alternative mechanisms associated with silencing of CDKN1C in Beckwith-Wiedemann syndrome.","date":"2005","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16061564","citation_count":17,"is_preprint":false},{"pmid":"29277274","id":"PMC_29277274","title":"Maternal high estradiol exposure alters CDKN1C and IGF2 expression in human placenta.","date":"2017","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/29277274","citation_count":16,"is_preprint":false},{"pmid":"33076988","id":"PMC_33076988","title":"Novel mutation points to a hot spot in CDKN1C causing Silver-Russell syndrome.","date":"2020","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/33076988","citation_count":16,"is_preprint":false},{"pmid":"25427884","id":"PMC_25427884","title":"Silver-Russell syndrome without body asymmetry in three patients with duplications of maternally derived chromosome 11p15 involving CDKN1C.","date":"2014","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25427884","citation_count":16,"is_preprint":false},{"pmid":"27402879","id":"PMC_27402879","title":"Parent-of-origin tumourigenesis is mediated by an essential imprinted modifier in SDHD-linked paragangliomas: SLC22A18 and CDKN1C are candidate tumour modifiers.","date":"2016","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27402879","citation_count":15,"is_preprint":false},{"pmid":"32015692","id":"PMC_32015692","title":"Silencing of microRNA-517a induces oxidative stress injury in melanoma cells via inactivation of the JNK signaling pathway by upregulating CDKN1C.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/32015692","citation_count":15,"is_preprint":false},{"pmid":"31976094","id":"PMC_31976094","title":"Familial Russell-Silver Syndrome like Phenotype in the PCNA Domain of the CDKN1C Gene, a Further Case.","date":"2019","source":"Case reports in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31976094","citation_count":15,"is_preprint":false},{"pmid":"34283053","id":"PMC_34283053","title":"miR-92b-3p Regulates Cell Cycle and Apoptosis by Targeting CDKN1C, Thereby Affecting the Sensitivity of Colorectal Cancer Cells to Chemotherapeutic Drugs.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34283053","citation_count":14,"is_preprint":false},{"pmid":"2276740","id":"PMC_2276740","title":"Molecular characterization of Beckwith-Wiedemann syndrome (BWS) patients with partial duplication of chromosome 11p excludes the gene MYOD1 from the BWS region.","date":"1990","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/2276740","citation_count":14,"is_preprint":false},{"pmid":"15696192","id":"PMC_15696192","title":"p57Kip2 (cdkn1c): sequence, splice variants and unique temporal and spatial expression pattern in the rat pancreas.","date":"2005","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15696192","citation_count":14,"is_preprint":false},{"pmid":"32024956","id":"PMC_32024956","title":"Role of the imprinted allele of the Cdkn1c gene in mouse neocortical development.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32024956","citation_count":14,"is_preprint":false},{"pmid":"22079941","id":"PMC_22079941","title":"Maternal gametic transmission of translocations or inversions of human chromosome 11p15.5 results in regional DNA hypermethylation and downregulation of CDKN1C expression.","date":"2011","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/22079941","citation_count":14,"is_preprint":false},{"pmid":"17610257","id":"PMC_17610257","title":"Cell cycle genes PEDF and CDKN1C in growing deer antlers.","date":"2007","source":"Anatomical record (Hoboken, N.J. : 2007)","url":"https://pubmed.ncbi.nlm.nih.gov/17610257","citation_count":13,"is_preprint":false},{"pmid":"30310057","id":"PMC_30310057","title":"Depletion of ZBTB38 potentiates the effects of DNA demethylating agents in cancer cells via CDKN1C mRNA up-regulation.","date":"2018","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30310057","citation_count":13,"is_preprint":false},{"pmid":"35770551","id":"PMC_35770551","title":"Epigenetic control of the imprinted growth regulator Cdkn1c in cadmium-induced placental dysfunction.","date":"2022","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/35770551","citation_count":12,"is_preprint":false},{"pmid":"34789717","id":"PMC_34789717","title":"Loss of MBD2 attenuates MLL-AF9-driven leukemogenesis by suppressing the leukemic cell cycle via CDKN1C.","date":"2021","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/34789717","citation_count":12,"is_preprint":false},{"pmid":"29207083","id":"PMC_29207083","title":"A type 2 diabetes-associated SNP in KCNQ1 (rs163184) modulates the binding activity of the locus for Sp3 and Lsd1/Kdm1a, potentially affecting CDKN1C expression.","date":"2017","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29207083","citation_count":12,"is_preprint":false},{"pmid":"36708218","id":"PMC_36708218","title":"Lappaol F regulates the cell cycle by activating CDKN1C/p57 in human colorectal cancer cells.","date":"2023","source":"Pharmaceutical biology","url":"https://pubmed.ncbi.nlm.nih.gov/36708218","citation_count":11,"is_preprint":false},{"pmid":"28508599","id":"PMC_28508599","title":"IMAGe and Related Undergrowth Syndromes: The Complex Spectrum of Gain-of-Function CDKN1C Mutations.","date":"2017","source":"Pediatric endocrinology reviews : PER","url":"https://pubmed.ncbi.nlm.nih.gov/28508599","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51656,"output_tokens":9136,"usd":0.146004,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19106,"output_tokens":5379,"usd":0.115002,"stage2_stop_reason":"end_turn"},"total_usd":0.261006,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2012,\n      \"finding\": \"Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome and result in loss of PCNA binding. Targeted expression of IMAGe-associated CDKN1C mutations in Drosophila caused severe eye growth defects compared to wild-type CDKN1C, indicating a gain-of-function mechanism. IMAGe mutations are distinct from BWS-causing mutations in CDKN1C.\",\n      \"method\": \"Identity-by-descent analysis, targeted exon capture/sequencing, dideoxy sequencing, Drosophila transgenic overexpression assay\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods including functional in vivo assay in Drosophila, sequencing validation, and PCNA-binding loss demonstrated; replicated across multiple unrelated patients\",\n      \"pmids\": [\"22634751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IMAGe-associated mutations in the PCNA-binding domain of CDKN1C dramatically increase protein stability via impaired proteasome-mediated degradation, explaining the gain-of-function reduced-growth phenotype. Wild-type CDKN1C is degraded via the proteasome (blocked by MG132), whereas IMAGe mutants (e.g. p.Ile272Ser, p.Asp274Asn, p.Phe276Val) are resistant to degradation. PCNA binding to CDKN1C is disrupted by these mutations.\",\n      \"method\": \"Western blotting with cycloheximide chase, proteasome inhibitor (MG132) treatment, co-immunoprecipitation for PCNA binding\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (cycloheximide chase, MG132 rescue, PCNA binding assay) in single rigorous study; finding replicated by independent lab (PMID 25861374)\",\n      \"pmids\": [\"24098681\", \"25861374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IMAGe-associated mutations in the PCNA-binding site of CDKN1C significantly increase CDKN1C protein stability and prevent cell cycle progression into S phase. Overexpression of either wild-type or BWS-mutant CDKN1C inhibited cell proliferation, but IMAGe-mutant CDKN1C decreased cell growth significantly more than wild-type or BWS protein.\",\n      \"method\": \"Flow cytometry cell cycle analysis, Western blotting, cell proliferation assays\",\n      \"journal\": \"Cell division\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean functional assays with multiple cell cycle readouts, single lab, corroborates PMID 24098681\",\n      \"pmids\": [\"25861374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CDKN1C interacts directly with E2F1, CDK7, and CDK9 in vivo and in vitro. CDKN1C is recruited to E2F1-regulated promoters and reduces RNA polymerase II CTD phosphorylation at Ser-2 and Ser-5 in an E2F1-dependent manner. CDKN1C blocks CDK7 and CDK9 ability to phosphorylate a GST-CTD fusion protein in vitro. The E2F1-CDKN1C interaction is mediated by two E2F1 domains.\",\n      \"method\": \"Adenoviral overexpression, RNA interference, chromatin immunoprecipitation (ChIP), in vitro kinase assay with GST-CTD, co-immunoprecipitation in vivo and in vitro\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods including in vitro kinase reconstitution, ChIP, reciprocal co-IP, siRNA knockdown with endogenous protein; single lab but rigorous\",\n      \"pmids\": [\"20106982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"miR-221 directly targets a site in the 3' UTR of CDKN1C/p57 mRNA to suppress its expression. Transfection of miR-221 into HCC-derived cells downregulates CDKN1C/p57 protein, and antimiR-221 upregulates it, promoting cell growth by increasing S-phase entry.\",\n      \"method\": \"miRNA transfection, antimiR transfection, luciferase reporter assay with 3'UTR, Western blotting, flow cytometry\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct 3'UTR reporter validation, gain and loss of function experiments, replicated in colorectal cancer (PMID 21278784)\",\n      \"pmids\": [\"18521080\", \"21278784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CDKN1C is a direct target of EZH2-mediated histone H3 lysine 27 trimethylation (H3K27me3) in breast cancer cells. EZH2 inhibition activates CDKN1C, synergistically enhanced by histone deacetylase inhibitor co-treatment.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) for H3K27me3, EZH2 knockdown/inhibition, gene expression analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP demonstrating direct EZH2/H3K27me3 at CDKN1C locus, replicated in multiple cancer contexts (PMID 29632530, 31367252, 33792119)\",\n      \"pmids\": [\"19340297\", \"29632530\", \"31367252\", \"33792119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Lsh (a SNF2-family chromatin remodeling protein) directly associates with the 5' differentially methylated region (DMR) at the Cdkn1c promoter by ChIP and controls CpG methylation at this DMR, specifically silencing the paternal Cdkn1c allele. Loss of Lsh reactivates the silenced paternal allele correlating with loss of 5'DMR methylation, without affecting KvDMR1 or other imprinted loci.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), allele-specific expression analysis, bisulfite sequencing of CpG methylation in Lsh-deficient mice\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct ChIP showing Lsh at Cdkn1c 5'DMR, allele-specific expression in KO model with methylation analysis; multiple orthogonal methods\",\n      \"pmids\": [\"15647320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The differentially methylated region (DMR) associated with mouse Cdkn1c is a CpG island beginning 600 bp 5' of the promoter. This methylation is not inherited from sperm but is acquired specifically on the paternal allele after implantation, is dependent on KvDMR1, and is required for maintaining but not establishing monoallelic Cdkn1c expression.\",\n      \"method\": \"Bisulfite sequencing, methylation analysis of gametes and postimplantation embryos, analysis of KvDMR1-deletion mouse model\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic analysis across developmental stages with KvDMR1-dependent genetic dissection; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"15533713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ZAC (a sequence-specific DNA-binding protein) binds within the CpG island of LIT1 (KCNQ1OT1) and induces LIT1 transcription in a methylation-dependent manner, suggesting ZAC regulates p57KIP2 (CDKN1C) through LIT1 in a novel imprinted gene network.\",\n      \"method\": \"DNA-binding assays, transfection reporter assays, methylation-dependent transcription assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct DNA-binding assay and transcriptional reporter, but the ZAC→LIT1→CDKN1C pathway is partially indirect; single lab\",\n      \"pmids\": [\"15888726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Enhancers for Cdkn1c expression in skeletal muscle and cartilage lie more than 25 kb downstream of the gene, demonstrating distant cis-regulation. BAC transgenes spanning 315 kb showed no allele-specific expression, suggesting the key imprinting element also lies at a distance from the gene.\",\n      \"method\": \"Bacterial artificial chromosome (BAC) transgenic mouse models, tissue-specific expression analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic BAC experiments directly establish cis-regulatory distance; single lab, clean genetic approach\",\n      \"pmids\": [\"11468278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Cdkn1c is the major regulator of embryonic growth within its IC2 imprinted domain in mice. Excess Cdkn1c (via BAC transgene copy number) causes dosage-dependent embryonic growth retardation and lethality associated with reduced Igf1 expression. Loss of Cdkn1c results in 11% heavier embryos with 2-fold increase in Igf1.\",\n      \"method\": \"BAC transgenic mouse models with varying copy numbers, embryonic weight measurements, gene expression analysis\",\n      \"journal\": \"BMC developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — dosage-response genetic experiment in mice with multiple copy number integrations and reciprocal loss-of-function; well-controlled mechanistic study\",\n      \"pmids\": [\"17517131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Cdkn1c mutant mouse embryos exhibit 20% overgrowth during gestation but experience growth reversal late in gestation. Cdkn1c deficiency causes marked placental dysfunction including thrombotic lesions in the labyrinth zone, loss of sinusoidal giant cells, and disordered trilaminar trophoblast layer, identifying a role for Cdkn1c in maintaining the maternal-fetal interface.\",\n      \"method\": \"Mouse genetic model, placental histology, embryonic weight analysis\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined cellular phenotype in KO model with specific placental histological readouts; single lab\",\n      \"pmids\": [\"21729874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Loss of maternal methylation (LOM) at KvDMR1 in BWS patients causes an 86-93% reduction in CDKN1C expression in fibroblast cells approximately 180 kb away on the maternal chromosome, without hypermethylation at the CDKN1C promoter itself.\",\n      \"method\": \"Quantitative PCR, ribonuclease protection assay, Southern hybridization with methylation-sensitive restriction endonuclease\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two orthogonal quantitative assays (qPCR + RPA) confirming dramatic expression loss, with promoter methylation ruled out by Southern analysis; replicated in human patient samples\",\n      \"pmids\": [\"14627666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ARX is a direct transcriptional repressor of CDKN1C in cortical progenitor cells. Loss of cortical ARX results in overexpression of CDKN1C, reduced intermediate progenitor cell (IPC) proliferation, and a reduction in upper-layer neurons.\",\n      \"method\": \"Conditional knockout mouse model (cortex-specific Arx cKO), transcriptional profiling, chromatin immunoprecipitation (ChIP) for ARX at Cdkn1c promoter, cortical cell counting\",\n      \"journal\": \"Cerebral cortex\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO model with defined neuronal phenotype plus direct ChIP demonstration of ARX at Cdkn1c; multiple orthogonal methods\",\n      \"pmids\": [\"23968833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CDKN1C is a downstream transcriptional target of SMARCB1 and is activated by increased histone H3 and H4 acetylation at its promoter. CDKN1C expression induces cell cycle arrest in rhabdoid tumor cells; siRNA knockdown of CDKN1C increases proliferation and competes against the anti-proliferative effect of restored SMARCB1. The HDAC inhibitor Romidepsin specifically restores CDKN1C expression through promoter histone acetylation.\",\n      \"method\": \"Inducible SMARCB1 expression system, siRNA knockdown, ChIP for histone H3/H4 acetylation at CDKN1C promoter, flow cytometry cell cycle analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including ChIP, inducible expression, siRNA rescue; specific mechanistic pathway established\",\n      \"pmids\": [\"19221586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Targeted demethylation of imprinting control region 2 (ICR2) using a TALE-TET1 fusion protein (ICR2-TET1) reduces CDKN1C/p57 expression and increases proliferation in human fibroblasts and islets. Human islets overexpressing ICR2-TET1 show repressed p57 with upregulated Ki-67 while maintaining glucose-sensing functionality; transplanted epigenetically edited islets show increased β cell replication in diabetic mice.\",\n      \"method\": \"Epigenetic editing with TALE-TET1 fusion, cell proliferation assays, Ki-67 staining, transplantation into diabetic immunodeficient mice\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct epigenetic editing experiment with functional in vivo transplantation validation; multiple orthogonal readouts\",\n      \"pmids\": [\"30352048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Cdkn1c is not expressed in quiescent muscle stem cells (MuSCs) but is induced in activated/proliferating myoblasts and maintained in differentiating myogenic cells. Cdkn1c subcellular localization is dynamic: initially cytoplasmic in activated/proliferating myoblasts, then progressively nuclear during differentiation to enforce growth arrest. Cdkn1c-deficient primary myoblasts display differentiation defects and increased proliferation.\",\n      \"method\": \"Mouse molecular genetics (conditional KO), live-cell imaging, subcellular fractionation, immunofluorescence, primary myoblast culture assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct imaging of dynamic subcellular localization tied to functional differentiation outcomes; genetic KO with defined phenotype; multiple orthogonal methods\",\n      \"pmids\": [\"30284969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Cdkn1c is induced by Hedgehog signaling in slow muscle precursor cells in zebrafish and cooperates with Myod to drive terminal differentiation of multiple early muscle fiber types. Myod in turn upregulates cdkn1c, forming a positive feedback loop that switches myogenic cells to terminal differentiation. Neither Hedgehog nor Cdkn1c is required for cell cycle exit per se.\",\n      \"method\": \"Zebrafish genetic analysis, morpholino knockdown, immunostaining, in situ hybridization, epistasis analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in zebrafish model with multiple orthogonal methods establishing pathway position; positive feedback loop experimentally demonstrated\",\n      \"pmids\": [\"21147088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Cdkn1c is a downstream target of MyoD during myogenic differentiation in C2C12 cells. MyoD-silenced clones show altered Cdkn1c expression, and bioinformatic and functional promoter studies demonstrate Cdkn1c dependence on MyoD activity.\",\n      \"method\": \"MyoD-silenced C2C12 clone generation, cDNA microarray, promoter functional analysis, quantitative PCR\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional promoter analysis combined with microarray and MyoD-KD; single lab\",\n      \"pmids\": [\"15890200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Paternal allelic mutation at the Kcnq1 locus reduces Kcnq1ot1 expression and increases Cdkn1c expression specifically on the paternal allele, reducing pancreatic β-cell mass. Histone modifications at the Cdkn1c promoter region in pancreatic islets contribute to this epigenetic regulation.\",\n      \"method\": \"Genetically modified mice (paternal vs maternal transmission), quantitative RT-PCR, histone modification ChIP in pancreatic islets, β-cell mass measurements\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — parent-of-origin genetic experiment with ChIP-verified histone modification at Cdkn1c promoter and functional β-cell mass phenotype; multiple orthogonal methods\",\n      \"pmids\": [\"26100882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Cdkn1c is required for development of the brown adipose lineage. Loss-of-function of Cdkn1c results in complete developmental failure of the brown adipocyte lineage. Cdkn1c is required for post-transcriptional accumulation of the brown fat determinant PRDM16, and CDKN1C and PRDM16 co-localize to the nucleus of rare label-retaining cells within interscapular brown adipose tissue.\",\n      \"method\": \"Mouse genetic models (gain and loss of function Cdkn1c), brown adipose tissue histology, immunostaining, ex vivo differentiation assays, co-localization imaging\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal gain/loss-of-function genetics with specific mechanistic link to PRDM16 protein stabilization; multiple orthogonal methods\",\n      \"pmids\": [\"26963625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cdkn1c has a cell-autonomous growth-promoting function in radial glial progenitor cells and nascent projection neurons in the cerebral cortex, mediating their survival. This is distinct from its non-cell-autonomous growth-inhibitory function. The growth-promoting function is dosage-sensitive but not subject to genomic imprinting.\",\n      \"method\": \"Mosaic Analysis with Double Markers (MADM) technology for single-cell resolution genetic dissection, cell counting, clonal analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — MADM provides single-cell resolution dissection of cell-autonomous vs non-cell-autonomous functions; rigorous genetic method with defined cellular phenotype\",\n      \"pmids\": [\"31924768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CDYL recruits EZH2 to the CDKN1C promoter region to regulate H3K27 trimethylation, causing transcriptional silencing of CDKN1C and promoting chemoresistance in small cell lung cancer. The CDYL/EZH2/CDKN1C axis was established by ChIP-qPCR, co-immunoprecipitation, GST pull-down, and EMSA assays.\",\n      \"method\": \"ChIP-qPCR, co-immunoprecipitation, GST pull-down, EMSA, mRNA sequencing, Western blotting, in vivo tumor models\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (ChIP, Co-IP, GST pulldown, EMSA) directly establishing CDYL-EZH2 interaction at CDKN1C promoter; in vitro and in vivo validation\",\n      \"pmids\": [\"31367252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Acute exposure to chromatin-modifying drugs causes temporary de-repression of the paternal (silent) Cdkn1c allele in mouse embryos. Chronic in utero maternal dietary protein deprivation causes permanent de-repression of imprinted Cdkn1c expression through a folate-dependent mechanism of DNA methylation loss at the paternal allele, sustained into adulthood.\",\n      \"method\": \"Allele-specific bioluminescent reporters (Cdkn1c-luciferase mice), in vivo live imaging, DNA methylation analysis, dietary manipulation studies\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct non-invasive allele-specific reporter system in vivo, mechanistic link to folate/DNA methylation established with multiple orthogonal assays\",\n      \"pmids\": [\"28147266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The paternal allele of Cdkn1c is expressed at a low level in the developing mouse neocortex. CNS-specific conditional deletion of the paternal allele results in marked reduction in brain size and reduction in neural stem-progenitor cell (NPC) number during neocortical development, reducing upper-layer neuron production.\",\n      \"method\": \"Conditional allele-specific KO mice (CNS-Cre for paternal allele), brain size measurement, immunostaining, NPC counting\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct genetic dissection of paternal allele-specific function with defined cellular phenotype; single lab\",\n      \"pmids\": [\"32024956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IGF2 promotes terminal differentiation of neural stem cells (NSCs) into astrocytes, neurons, and oligodendrocytes by inducing Cdkn1c/p57 expression. Using intraventricular infusion of recombinant IGF2 in Cdkn1c-deficient NSC conditional mutants, p57 was confirmed to partially mediate IGF2's differentiation effects independently of its role in cell-cycle progression.\",\n      \"method\": \"Conditional KO of Cdkn1c in NSCs, intraventricular infusion of recombinant IGF2, lineage analysis, genetic epistasis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with conditional KO combined with recombinant protein rescue; established pathway position of CDKN1C downstream of IGF2 in NSC differentiation\",\n      \"pmids\": [\"36633189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CDKN1C mutation p.Arg279Leu in the PCNA-binding domain causes familial RSS phenotype. Functional analysis showed this mutation did not affect the cell cycle (unlike IMAGe mutations), but led to increased CDKN1C protein stability. The IMAGe mutation p.Arg279Pro caused gain-of-function cell cycle effects.\",\n      \"method\": \"Flow cytometry cell cycle analysis, Western blotting with cycloheximide to assess stability, Sanger sequencing\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional assays (cell cycle, protein stability) distinguishing RSS from IMAGe mutations; single lab\",\n      \"pmids\": [\"24065356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Cdkn1c elevated expression in the brain (in a transgenic loss-of-imprinting model) leads to altered dopaminergic gene expression, increased tyrosine hydroxylase staining, and increased dopamine tissue content in the striatum, indicating a functional role for Cdkn1c dosage in midbrain dopaminergic neuron development and behavior.\",\n      \"method\": \"Cdkn1c BAC transgenic (Cdkn1cBACx1) mouse model, tyrosine hydroxylase immunostaining, HPLC dopamine quantification, c-fos expression, behavioral assays\",\n      \"journal\": \"Genes, brain, and behavior\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined cellular and behavioral phenotype in transgenic model with multiple neurochemical readouts; single lab\",\n      \"pmids\": [\"28857482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Hes1 (a Notch effector) directly represses CDKN1C/P57 transcription in hepatocellular carcinoma cells. Downregulation of Notch1/3 leads to Hes1 downregulation and CDKN1C/P57 upregulation. CDKN1C/P57 upregulation induces cellular senescence (senescence-associated β-galactosidase accumulation, P16 increase, morphological changes) without affecting apoptosis.\",\n      \"method\": \"siRNA knockdown of Notch1/Notch3/Hes1, cDNA transfection of CDKN1C, flow cytometry, senescence-associated β-galactosidase assay, Western blotting\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional pathway dissection with genetic epistasis (Hes1/CDKN1C double depletion confirming senescence dependence on CDKN1C); single lab\",\n      \"pmids\": [\"22705236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miR-222 derived from M1 macrophage exosomes promotes vascular smooth muscle cell (VSMC) proliferation and migration by targeting CDKN1C (and CDKN1B). These exosomes are taken up by VSMCs through macropinocytosis, and miR-222 inhibitor abolishes this effect in vitro and in vivo.\",\n      \"method\": \"Transwell co-culture, exosome isolation, microRNA array, luciferase reporter assay for 3'UTR targeting, carotid artery ligation model, miR-222 inhibitor treatment\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — 3'UTR direct targeting validated by reporter assay, in vitro and in vivo functional confirmation; single lab\",\n      \"pmids\": [\"31142732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Ezh2 represses Cdkn1c (and Cdkn2a) in activated naive CD8+ T cells by H3K27me3 at these gene loci. Deletion of Ezh2 in CD8+ T cells increases Cdkn1c and Cdkn2a expression and impairs activation-induced proliferation with prolonged cell division times.\",\n      \"method\": \"Conditional Ezh2 KO mice (Ezh2fl/fl Cd4Cre+ and GzmBCre+), ChIP for H3K27me3, quantitative PCR, real-time live imaging of cell division\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP directly demonstrating H3K27me3 at Cdkn1c locus in Ezh2 KO T cells, two conditional KO models dissecting temporal requirements, live imaging readout\",\n      \"pmids\": [\"29632530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MBD2 (a DNA methylation reader) promotes leukemic stem cell (LSC) cycle progression through epigenetic regulation of CDKN1C transcription by binding to its promoter region. Loss of MBD2 delays MLL-AF9-driven leukemia initiation and progression via increased CDKN1C expression.\",\n      \"method\": \"MBD2 knockout in MLL-AF9 murine leukemia model, serial transplantation, gene expression analysis, bioinformatics, MBD2 ChIP at CDKN1C promoter\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO model with defined leukemia phenotype and ChIP evidence for MBD2 binding at CDKN1C promoter; single lab\",\n      \"pmids\": [\"34789717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"miR-25 directly targets the 3'UTR of CDKN1C to reduce its protein levels, increasing glioma cell proliferation. Ablation of endogenous miR-25 rescues CDKN1C expression and decreases glioma cell proliferation. Downregulation of CDKN1C by siRNA blocked the antiproliferative activity of miR-25 inhibition.\",\n      \"method\": \"3'UTR luciferase reporter assay, miR-25 overexpression/knockdown, siRNA, cell proliferation assays, flow cytometry\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct 3'UTR reporter assay with functional rescue by siRNA; single lab\",\n      \"pmids\": [\"25960208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The T2DM-associated SNP rs163184 in the KCNQ1 intronic region modulates binding of Sp3 and Lsd1/Kdm1a in an allele-specific manner. Sp3 binds preferentially to the non-risk allele and stimulates transcriptional activity. Lsd1/Kdm1a is preferentially recruited to the non-risk allele and reduces Sp3-dependent transcriptional activity. SP3 knockdown upregulates CDKN1C expression in cells with non-risk alleles.\",\n      \"method\": \"DNA pulldown with allele-specific probes, mass spectrometry protein identification, artificial promoter reporter assay, SP3 siRNA knockdown, gene expression analysis\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — allele-specific protein binding and functional promoter assays; indirect link to CDKN1C through SP3; single lab\",\n      \"pmids\": [\"29207083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CTCF binding sites are present within the unmethylated CDKN1C gene body CpG island in human placenta. Putative enhancer regions containing H3K4me1 and H3K27ac marks are located approximately 58 and 360 kb from CDKN1C. 3C-PCR identifies constitutive higher-order chromatin loops between one of these enhancer regions and CDKN1C in human placenta.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) for CTCF and histone marks, Chromosome Conformation Capture (3C-PCR)\",\n      \"journal\": \"Frontiers in genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP and 3C-PCR demonstrating CTCF binding and chromatin loops; single lab, focused on placenta\",\n      \"pmids\": [\"27200075\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CDKN1C/p57KIP2 is a maternally expressed, imprinted cyclin-dependent kinase inhibitor whose expression is controlled by KvDMR1/ICR2 methylation and multiple epigenetic mechanisms including EZH2/EZH1-mediated H3K27me3, Lsh-dependent CpG methylation at its 5' DMR, and SMARCB1-dependent histone acetylation; it inhibits cell-cycle progression by binding cyclin/CDK complexes, suppressing RNA polymerase II CTD phosphorylation via E2F1-directed recruitment to inhibit CDK7/CDK9, and its PCNA-binding domain regulates protein stability (loss of PCNA binding stabilizes the protein causing gain-of-function growth restriction in IMAGe syndrome, while loss-of-function causes overgrowth in Beckwith-Wiedemann syndrome); beyond cell-cycle arrest, CDKN1C plays cell-autonomous roles in radial glial progenitor survival, myoblast differentiation (via cytoplasmic-to-nuclear translocation), brown adipose tissue development (promoting PRDM16 accumulation), and dopaminergic neuron function, and is regulated post-transcriptionally by multiple miRNAs (miR-221, miR-25, miR-222, miR-199a-5p) targeting its 3'UTR.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CDKN1C/p57KIP2 is a maternally expressed, imprinted cyclin-dependent kinase inhibitor that restrains cell proliferation and controls embryonic and tissue growth in a strictly dosage-sensitive manner [#10]. Its expression is set by a layered epigenetic architecture: imprinted silencing of the paternal allele depends on a 5' differentially methylated region whose CpG methylation is acquired after implantation under control of the distal KvDMR1/ICR2 and enforced by the chromatin remodeler Lsh [#7, #6], while regulation also occurs over long distances through enhancers and CTCF-anchored chromatin loops tens to hundreds of kilobases from the gene [#9, #34]; loss of maternal KvDMR1 methylation collapses CDKN1C expression in cis without altering the promoter itself [#12]. Beyond imprinting, CDKN1C transcription is gated by Polycomb EZH2/H3K27me3 — recruited via partners such as CDYL — and by SMARCB1-dependent promoter histone acetylation, and is repressed by transcription factors including ARX and the Notch effector Hes1, the latter coupling CDKN1C induction to cellular senescence [#5, #22, #14, #13, #28]. Mechanistically, CDKN1C is recruited to E2F1-regulated promoters where it binds E2F1, CDK7 and CDK9 and suppresses RNA polymerase II CTD phosphorylation at Ser-2 and Ser-5, directly linking it to transcriptional control of the cell cycle [#3]. Its activity is tuned post-transcriptionally by proteasomal turnover gated through a PCNA-binding domain and by 3'UTR-targeting miRNAs (miR-221, miR-25, miR-222) [#1, #4, #32, #29]. Mutations in the PCNA-binding domain that abolish PCNA binding stabilize the protein and produce a gain-of-function growth-restriction phenotype causing IMAGe syndrome, distinct from loss-of-function overgrowth, with a related stabilizing mutation underlying a familial Russell-Silver phenotype [#0, #1, #26]. CDKN1C also carries growth-restricting and, separately, cell-autonomous growth-promoting/survival roles in defined lineages: it enforces myoblast differentiation through dynamic cytoplasmic-to-nuclear translocation and a MyoD feedback loop, drives terminal differentiation of neural stem cells downstream of IGF2, supports radial glial progenitor survival, and is required for brown adipose development via post-transcriptional accumulation of PRDM16 [#16, #17, #25, #21, #20].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Established that monoallelic CDKN1C expression depends on a post-implantation-acquired 5' DMR methylation mark rather than a gamete-inherited one, redefining how the imprint is maintained.\",\n      \"evidence\": \"Bisulfite sequencing across gametes and embryos plus KvDMR1-deletion mouse analysis\",\n      \"pmids\": [\"15533713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not identify the enzymes that acquire the paternal methylation\", \"Mechanism by which KvDMR1 directs the distal mark unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified the chromatin remodeler Lsh as a direct effector that establishes 5'DMR CpG methylation to silence the paternal allele, providing a molecular actor for the imprint.\",\n      \"evidence\": \"ChIP, allele-specific expression and bisulfite sequencing in Lsh-deficient mice\",\n      \"pmids\": [\"15647320\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Lsh is targeted specifically to the paternal 5'DMR unknown\", \"Relationship to KvDMR1 control not fully defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed that loss of maternal KvDMR1 methylation in BWS patients reduces CDKN1C expression by >85% from ~180 kb away without promoter hypermethylation, linking a distal imprinting defect to disease through long-range cis regulation.\",\n      \"evidence\": \"qPCR, RNase protection and methylation-sensitive Southern in patient fibroblasts\",\n      \"pmids\": [\"14627666\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physical mechanism connecting KvDMR1 to CDKN1C silencing not shown\", \"Cell-type specificity beyond fibroblasts not addressed\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrated that CDKN1C is the dominant dosage-sensitive growth regulator of its imprinted domain, with bidirectional effects on embryo size linked to Igf1.\",\n      \"evidence\": \"BAC transgenic copy-number series and reciprocal loss-of-function in mice\",\n      \"pmids\": [\"17517131\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular link between CDKN1C and Igf1 not defined\", \"Tissue origin of growth effect not localized\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Revealed a transcriptional mechanism beyond classical CDK inhibition: CDKN1C is recruited to E2F1 promoters and suppresses Pol II CTD phosphorylation by inhibiting CDK7 and CDK9.\",\n      \"evidence\": \"In vivo/in vitro co-IP, ChIP, siRNA, and in vitro GST-CTD kinase assays\",\n      \"pmids\": [\"20106982\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide scope of E2F1-directed recruitment unknown\", \"Physiological contexts where this dominates over cyclin/CDK inhibition unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined the molecular basis of IMAGe syndrome as gain-of-function PCNA-binding-domain mutations distinct from BWS loss-of-function, establishing a domain-specific genotype-phenotype split.\",\n      \"evidence\": \"IBD mapping, exon sequencing, and Drosophila transgenic overexpression\",\n      \"pmids\": [\"22634751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular mechanism of gain-of-function not yet explained in this study\", \"Role of PCNA binding in normal regulation undefined here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Explained the IMAGe gain-of-function as impaired proteasomal degradation via loss of PCNA binding, identifying protein stability as a key regulatory node.\",\n      \"evidence\": \"Cycloheximide chase, MG132 rescue and PCNA co-IP; replicated independently\",\n      \"pmids\": [\"24098681\", \"25861374\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase mediating PCNA-dependent turnover not identified\", \"Whether PCNA binding directly couples to degradation machinery unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Distinguished a related familial Russell-Silver-causing PCNA-domain mutation that stabilizes protein without altering the cell cycle, refining the allelic-series model.\",\n      \"evidence\": \"Cell-cycle flow cytometry, cycloheximide stability assay and Sanger sequencing\",\n      \"pmids\": [\"24065356\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; mechanism distinguishing RSS from IMAGe phenotypically not fully resolved\", \"How stability without cell-cycle change produces growth restriction unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Placed CDKN1C under Polycomb control, showing EZH2/H3K27me3 directly silences it and is reversible by combined EZH2 and HDAC inhibition.\",\n      \"evidence\": \"ChIP for H3K27me3 with EZH2 knockdown/inhibition; replicated across cancers\",\n      \"pmids\": [\"19340297\", \"29632530\", \"31367252\", \"33792119\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Recruitment specificity of EZH2 to the locus not addressed here\", \"Interaction with imprinting machinery unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified CDYL as a recruiter of EZH2 to the CDKN1C promoter, supplying a targeting mechanism for Polycomb silencing linked to chemoresistance.\",\n      \"evidence\": \"ChIP-qPCR, co-IP, GST pull-down, EMSA and in vivo tumor models\",\n      \"pmids\": [\"31367252\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of CDYL-dependent recruitment beyond SCLC unknown\", \"Signals controlling CDYL engagement undefined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Connected SMARCB1/SWI-SNF to CDKN1C activation through promoter histone acetylation, establishing a tumor-suppressor axis in rhabdoid tumors.\",\n      \"evidence\": \"Inducible SMARCB1, siRNA rescue, acetylation ChIP and cell-cycle analysis\",\n      \"pmids\": [\"19221586\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect SMARCB1 action at the promoter not fully separated\", \"Interplay with Polycomb silencing not tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed ARX directly represses CDKN1C in cortical progenitors, tying its dosage to intermediate progenitor proliferation and neuronal output.\",\n      \"evidence\": \"Cortex-specific Arx cKO, expression profiling and ChIP at the promoter\",\n      \"pmids\": [\"23968833\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether repression is direct transcriptional or context-dependent not fully resolved\", \"Cofactors of ARX at the locus unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established post-transcriptional control of CDKN1C by miR-221 acting on its 3'UTR, linking miRNA dysregulation to proliferative phenotypes.\",\n      \"evidence\": \"miR/antimiR transfection, 3'UTR luciferase reporter, Western and flow cytometry; replicated\",\n      \"pmids\": [\"18521080\", \"21278784\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution versus transcriptional control in vivo unclear\", \"Tissue-specific miRNA regulation not mapped\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated dynamic cytoplasmic-to-nuclear translocation of CDKN1C as the switch enforcing myoblast growth arrest and differentiation.\",\n      \"evidence\": \"Conditional KO, live imaging, subcellular fractionation and primary myoblast assays\",\n      \"pmids\": [\"30284969\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals driving the localization switch not identified\", \"Cytoplasmic function molecular targets undefined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Positioned Cdkn1c in a Hedgehog-Myod positive-feedback loop driving terminal muscle differentiation independent of cell-cycle exit.\",\n      \"evidence\": \"Zebrafish genetic epistasis, morpholino knockdown and in situ analysis\",\n      \"pmids\": [\"21147088\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of cell-cycle-independent differentiation role unresolved\", \"Conservation of the loop in mammals not tested here\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified a lineage-specific role in which Cdkn1c is required for brown adipose development through post-transcriptional accumulation of PRDM16.\",\n      \"evidence\": \"Reciprocal gain/loss-of-function mice, BAT histology and co-localization imaging\",\n      \"pmids\": [\"26963625\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which CDKN1C stabilizes PRDM16 not defined\", \"Whether nuclear co-localization is required mechanistically unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Resolved a cell-autonomous, non-imprinted growth-promoting/survival function of Cdkn1c in radial glial progenitors, opposite to its non-cell-autonomous inhibitory role.\",\n      \"evidence\": \"MADM single-cell-resolution clonal genetic analysis\",\n      \"pmids\": [\"31924768\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular pathway of the pro-survival function unknown\", \"How a CDK inhibitor promotes growth mechanistically unexplained\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Placed Cdkn1c downstream of IGF2 as a partial mediator of neural stem cell terminal differentiation, separating its differentiation role from cell-cycle control.\",\n      \"evidence\": \"Conditional Cdkn1c KO with recombinant IGF2 infusion and lineage epistasis\",\n      \"pmids\": [\"36633189\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other IGF2 effectors not identified\", \"Direct molecular link between IGF2 signaling and Cdkn1c induction unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CDKN1C's opposing cell-autonomous growth-promoting and non-cell-autonomous growth-inhibitory functions are molecularly partitioned, and which degradation machinery couples PCNA binding to turnover, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase for PCNA-dependent CDKN1C degradation unidentified\", \"Mechanism of growth-promoting function uncharacterized\", \"Integration of imprinting, Polycomb, and SWI-SNF inputs at one locus not unified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 10, 2]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [16, 20]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [10, 16, 17, 20, 21, 25]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [5, 6, 14, 22]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 13, 28]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 12, 26]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PCNA\", \"E2F1\", \"CDK7\", \"CDK9\", \"PRDM16\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":7,"faith_total":7,"faith_pct":100.0}}